Formulation and Evaluation of Solid Dispersions of an Anti-diabetic Drug

The present work investigates thedissolution and bioavailability characteristics ofan anti-diabetic drug, Glimepiride. Glimepiride,is an oral hypoglycemic drug and has problemsin bioavailability and bioequivalence due to itspoor water solubility. In the present study,dissolution studies were carried out by using USPXXIV apparatus, for the drug glimepiride, andits binary systems (both physical mixture as wellas solid dispersions of glimepiride). Infrared (IR)Spectroscopy, Differential Scanning Calorimetry(DSC), and X-ray Diffractometry (XRD) wereperformed to identify any physicochemicalinteraction between the drug and the carrier andits effect on dissolution behavior. Tabletscontaining solid dispersion products wereformulated and compared with the commercialproduct. The commercial product and the tabletformulation under investigation were thancharacterized for their various physicochemicalproperties such as weight variation, % friability,disintegration and in vitro dissolution profiles. IRSpectroscopy, XRD, and DSC showed no changein the crystal structure of glimepiride thusindicating the absence of any interaction betweenthe drug and the polymer. A significantimprovement in the dissolution of glimepiride insolid dispersion products has been observed(>85% in 5 minutes). Also tablets containing soliddispersion exhibited better dissolution profile thancommercial tablets. Thus, the solid dispersion
technique can be successfully used for theimprovement of dissolution of glimepiride.

To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2014 ABAP Awards

Invitation for Nominations to 2014 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before September 10, 2014 in the prescribed format.



Upcoming 0 events

  • No upcoming events available

User login


  • Site Counter: 1,712,415
  • Unique Visitor: 127,000
  • Registered Users: 15,460
  • Your IP:
  • Since: 2010-03-21